At a Glance
  • Status: Active Consortium
  • Year Launched: 2014
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • Disease focus:
    Alzheimer's Disease, Parkinson's Disease
  • Location: Europe
aetionomy

Abstract

The AETIONOMY consortium is part of the Innovative Medicines Initiative (IMI) and aims to collect data that could be used to create taxonomies for neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. The focus of the taxonomy is based on molecular causes, rather than symptoms, with the goal of facilitating development of more effective and targeted treatments. 

Mission

AETIONOMY was founded to establish mechanism-based taxonomies for Alzheimer’s and Parkinson’s diseases and other neurodegenerative disorders (NDD). To do this, the consortium collects and analyzes data to:

  1. create new ways to combine underutilized data currently available in the literature, public databases, and from private companies

  2. determine how to dynamically organize and structure different types of knowledge about NDD

  3. determine how to apply this knowledge to construct new patient group classification

  4. identify correlations between disease features at molecular, tissue or organ-specific, and clinical levels

  5. identify sub-groups of patients based on the molecular cause of their disease, as opposed to the nature and location of their symptoms

  6. deliver data, tools, and recommendations for the biomedical community in the treatment of NDD

A mechanism-based taxonomy is hoped to advance the (a) description and organization of the indication-specific data and (b) linking of data to disease models, based on causal and correlative relationships.

The expected outcome of AETIONOMY is a new NDD taxonomy system that distinguishes mixed pathologies, allowing for new features or classes to be added into the taxonomy, all with the goal of aiding drug and biomarker discovery.

Consortium History

AETIONOMY is the result of IMI’s eighth call for proposals, which included a call to develop aetiology-based taxonomy for human diseases. The project is based on methodology submitted by Fraunhofer SCAI and will build on work done in two other IMI consortia—OpenPHACTS.

AETIONOMY was launched in 2014 with a lifetime of five years. Disease modeling, data mining, and developing a knowledge base are the first work streams to launch in the initial three years. Patient recruitment will begin in year 2, and testing of disease mechanism is scheduled to begin in year 3.

A joint conference of IMI/European Union (EU) Neurodegenerative Diseases Research Projects working on neurodegenerative diseases is planned for November 2015. The final AETIONOMY Symposium on Neurodegenerative Research of Alzheimer’s and Parkinson’s Diseases will be held in 2017.

Structure & Governance

There are 12 academic partners involved in AETIONOMY: 4 clinical partners, 4 European Federation of Pharmaceutical Industries and Associations (EFPIA) member organizations (pharmaceutical industry), 2 small-to-medium sized businesses, and 2 patient organizations. The initiative is managed on a tiered structure, with a Steering Committee, General Assembly, and Project Office. The project is divided into five separate work streams:

Financing

AETIONOMY has a total budget of €17.8 million. IMI provides €8.0 million, EFPIA in-kind is funding €8.0 million, and other sources are covering the remaining €1.8 million.

Intellectual Property

All IMI projects, like AETIONOMY, operate under the same umbrella intellectual (IP) policy. Any IP discovered as a result of work in the collaboration is owned by the participating institution that made the discovery (or if the discovery was made jointly, there is joint ownership). Other participants have access rights to the generated IP during and after the project for research use, and participant owners have the right to license their IP and associated obligations to other parties, including to affiliated entities. Third parties may request access rights, which do not involve the ability to sublicense without receiving authorization from the IP-owning participant.

Impact/Accomplishment

Tamas Letoha, CEO of Pharmacoida and an AETIOLOGY scientist, won the 2013 award for Hungarian Young Entrepreneur of the Year.

Resulting publications from AETIONOMY can be found at http://www.aetionomy.eu/index.php?id=5306

Points of Contact

Duncan McHale
Project Coordinator, UCB
phone: +44 1753 447620
email: Duncan.mchale@ucb.com

Laurent Schots
Media Relations, UCB
phone: +32 2 559 9264

Dr. Martin Hofmann-Apitius
Head of the Department of Bioinformatics
Fraunhofer Institute for Algorithms and Scientific Computing SCAI
53754 Sankt Augustin, Germany
phone: +49 2241 14 2802
email: martin.hofmann-apitius@scai.fraunhofer.de

Sponsors & Partners

Alzheimer Europe

Boehringer Ingelheim Pharma

Consorci Institut D’Investigacions Biomediques August Pi i Sunyer

Erasmus Universitair Medisch Centrum Rotterdam

European Brain Council

Fraunhofer-Gesellschaft zur Förderung der angewandten Fourschung e.V.

Gottfried Wilhelm Leibnez Universitaet Hannover

Institut du Cerveau et de la Moelle épinière

Karolinska Institutet

Novartis Pharma AG

Pharmacoidea Development and Service Ltd.

Sanofi-Aventis Research and Development

SC NEURORAD SRL

UCB Pharma SA

Universitätsklinikum Bonn

University College London

University of Luxembourg


Last Updated: 04/22/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.